World Idiopathic Pulmonary Fibrosis Market Examined by Black Swan Analysis in Its Report Published at MarketPublishers.com01 Feb 2016 • by Natalie Aster
LONDON – Idiopathic pulmonary fibrosis (IPF) is the most common type of interstitial lung disease (ILD), and a specific form of chronic, progressive, fibrosing interstitial pneumonia. The etiology of this medical condition is not known (hence the term idiopathic), however, some possible causes (triggers) of the disorder could include smoking and exposure to various dusts, viral infections, specific medicines, etc. Amid the key symptoms and comorbidities for IPF one can name gastro-oesophageal reflux disease (GORD), heart disease, presence of clubbing and air ventilation assistance.
The global idiopathic pulmonary fibrosis (IPF) market is poised to grow at a healthy CAGR over the forecast period. Earlier, the IPF market was underserved due to a lack of approved products. In December 2008, Japan’s Shionogi launched Pirespa (generic name pirfenidone) in the country. This promising therapeutic agent is expected to inhibit the progression of IPF through a new MoA inhibiting fibrosis directly and providing a novel IPF treatment option. In May, 2011, Shionogi concluded the license agreement with Seoul-based Ildong Pharmaceuticals Co., Ltd. for the sale of pirfenidone in South Korea. In July, 2012, the Korean company received a marketing and manufacturing approval for IPF treatment of Pirespa ® 200mg tablet.
The sales of Pirespa are likely to increase owing to its projected approval in the USA and the EU as well as the projected approval and further launch of Gilead's Letiaris and Actelion's Tracleer. The use of off-label drugs also contributes to the growth of the IPF market.
Comprehensive research report “Epiomic Epidemiology Series: Idiopathic Pulmonary Fibrosis Forecast in 9 Major Markets 2015-2025” elaborated by Black Swan Analysis covers the IPF market, providing the current prevalent population for IPF across 9 leading markets – the USA, Germany, France, Spain, Italy, Brazil, the UK, Japan and India, broken down by gender and 5-year age cohort. The report uncoveres the development of prospective products, launch plans and pricing strategies; provides in-depth insights into the prevalence of the subdivided IPF types and identifies what patient segments have high potential. It offers information on the pertinent clinical trials across various countries, limelights the impact of certain comorbid conditions on the prevalent population within IPF; determines IPF’s subpopulations which are in need of treatment; as well as reviews the markets with the biggest pool of IPF patients.
Epiomic Epidemiology Series: Idiopathic Pulmonary Fibrosis Forecast in 9 Major Markets 2015-2025
Published: December, 2015
Price: US$ 6,382.00
More studies by the publisher can be found at Black Swan Analysis page.